Free Trial
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel
NASDAQ:CRBP

Corbus Pharmaceuticals Q3 2026 Earnings Date & Estimates

Corbus Pharmaceuticals logo
$4.53 +0.12 (+2.61%)
As of 12:08 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Corbus Pharmaceuticals is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. The conference call is scheduled for November 6, 2026 at 12:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
12:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Corbus Pharmaceuticals in Q3 2026

Corbus Pharmaceuticals is expected to post earnings of -$1.2141 per share on revenue of $2.00 million. In the same quarter a year earlier Corbus Pharmaceuticals reported -$1.90 per share. Corbus Pharmaceuticals last reported on August 6, 2026, posting -$1.81 per share and missing the -$1.26 consensus estimate. Corbus Pharmaceuticals has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$1.2141
Expected Revenue
$2.00 million
Prior-Year EPS
-$1.90

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$1.81 (Missed by -$0.55)
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Corbus Pharmaceuticals Q3 2026 Earnings FAQ

Corbus Pharmaceuticals (NASDAQ:CRBP) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Corbus Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Corbus Pharmaceuticals to post earnings of -$1.2141 per share for Q3 2026.

The consensus revenue estimate for Corbus Pharmaceuticals is $2.00 million for Q3 2026.

Corbus Pharmaceuticals Earnings Headlines

Corbus Pharmaceuticals Holdings, Inc. Announces First Patient Dosed in Tempo-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer
September 29, 2026  |  marketscreener.comM
Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer
September 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/29/3370767/0/en/corbus-pharmaceuticals-announces-first-patient-dosed-in-tempo-1-registrational-study-of-crb-701-in-patients-with-2l-oropharyngeal-cancer.html
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.tc pixel
October 15 at 1:00 AM  |  Stansberry Research (Ad)
Wedbush Keeps Their Buy Rating on Corbus Pharmaceuticals (CRBP)
September 17, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/CRBP/pressreleases/4632551/wedbush-keeps-their-buy-rating-on-corbus-pharmaceuticals-crbp/
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Phase 1b Topline Results for CRB-913 in Obesity and Potential as Weight Loss Therapy Transcript
September 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4946134-corbus-pharmaceuticals-holdings-inc-crbp-phase-1b-topline-results-for-crbminus-913-in-obesity
Corbus Pharmaceuticals Shares Rise 12% After CANYON-1 Obesity Trial Data
September 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/corbus-pharmaceuticals-shares-rise-12-132826287.html
See More Corbus Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Corbus Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Corbus Pharmaceuticals and other key companies, straight to your email.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals (NASDAQ:CRBP) is a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases, with an emphasis on oncology and immunology. The company’s research programs are designed to address biological pathways involved in tumor growth, disease progression and immune regulation.

Corbus’ oncology pipeline includes CRB-701, an antibody-drug conjugate designed to target Nectin-4, and CRB-601, an investigational monoclonal antibody that targets integrins involved in tumor biology and the tumor microenvironment. The company has also advanced earlier immunology programs, including lenabasum, an oral cannabinoid receptor type 2 agonist that was investigated in inflammatory and fibrotic diseases.

Founded in 2009 and headquartered in Norwood, Massachusetts, Corbus conducts research and clinical development activities through its U.S. operations and collaborations. The company is led by Yuval Cohen, Ph.D., who serves as chief executive officer and has guided Corbus through its strategic expansion into oncology.

View Corbus Pharmaceuticals Profile
Earnings Tools